PREX1 and breast carcinoma: P-Rex1 has been shown to be overexpressed in prostate cancer, breast cancer, and melanoma, and this is associated with tumor metastasis and poor patient outcome (Lindsay et al., 2011, Montero et al., 2011, Qin et al., 2009, Sosa et al., 2010).